Medical Bulletin 10/August/2026

• The FDA approved updated 2026-2027 COVID-19 vaccines targeting the XFG variant on August 27, with doses shipping immediately to pharmacies, hospitals, and clinics. • While the vaccines are now physically available across the country, federal eligibility guidance remains unsettled, leaving uncertainty regarding who qualifies for the shots.

• The FDA has approved new COVID-19 vaccines for the 2026-2027 season, specifically designed to target the XFG variant. • The vaccines are approved for adults aged 65 and older, with eligibility extended to younger individuals in high-risk groups depending on the specific shot.

• The FDA has approved updated COVID-19 vaccines designed to protect against the latest circulating strains of the virus. • Health officials emphasize that these vaccines are most effective at preventing severe disease, hospitalizations, and ICU admissions.

• The U.S. FDA has approved a supplemental Biologics License Application for Pfizer and BioNTech’s 2026-2027 COVID-19 vaccine formula. • The updated vaccine, COMIRNATY ® XFG, specifically targets the XFG variant to better align with currently circulating strains of the virus.

• The U.S. Food and Drug Administration (FDA) has approved a new daily pill developed by Revolution Medicines for the treatment of pancreatic cancer. • This groundbreaking medication introduces a novel therapeutic approach to combat one of the most lethal forms of cancer.

• The U.S. FDA has granted speedy approval to a groundbreaking pancreatic cancer drug developed by Revolution Medicines. • In a large-scale trial, the therapy demonstrated the ability to double the survival rate for patients suffering from advanced, metastatic disease.

• The US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-a-kind oral medication designed to treat the most common form of pancreatic cancer. • Developed by Revolution Medicines, the drug functions as a Ras multiselective inhibitor, targeting specific genetic drivers of the disease.

• The U.S. has approved daraxonrasib, a breakthrough drug designed to treat pancreatic cancer, which is widely regarded as one of the most serious and difficult-to-treat malignancies. • Unlike traditional chemotherapy, this medication specifically targets the activated KRAS protein found within pancreatic cancer cells to inhibit tumor growth.

• Researchers analyzed the impact of the 21st Century Cures Act, which allows the FDA to approve novel drugs based on a single pivotal trial rather than multiple studies. • Findings indicate that since 2016, the number of studies supporting new drug approvals in the US has steadily decreased.

• The FDA has approved a landmark drug designed to treat pancreatic cancer, one of the deadliest forms of the disease. • The medication utilizes a new therapeutic approach by blocking a specific protein that fuels tumor growth in the vast majority of pancreatic cancer cases.

• A new analysis reveals that more than two-thirds of new drugs approved by the FDA in 2024 were sanctioned based on the findings of a single study. • The report indicates a steady decline in the number of studies required for drug approval since 2016, raising concerns about the rigor of the process.

• Researchers discovered that gut microbes may begin consuming proteins from the protective mucus lining of the gut when their fiber intake is limited. • The study highlights that dietary fiber acts as a critical suppressant to this process, preventing microbes from damaging the intestinal barrier.